Liposomal tretinoin for uncomplicated acne vulgaris

Schäfer‐Korting, Monika; Hc, Korting; Ponce-Pöschl, E.

doi:10.1007/bf00577761

Cited by 69 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schäfer-Korting et al [37] investigated the effi cacy and local tolerability of liposomal tretinoin in a double-blind study involving 20 patients with uncomplicated acne vulgaris. The patients received liposomal tretinoin (0.01%) on one side of the body and a commercial gel preparation with either 0.025% or 0.05% of tretinoin on the other side once daily for 10 weeks.…”

Section: Overview Of Various Novel Drug Delivery Strategiesmentioning

confidence: 99%

Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents

Date

Naik²,

Nagarsenker³

2005

Skin Pharmacol Physiol

107

View full text Add to dashboard Cite

Acne is the most common cutaneous disorder of multifactorial origin with a prevalence of 70–85% in adolescents. The majority of the acne sufferers exhibit mild to moderate acne initially, which progresses to the severe form in certain cases. Topical therapy is employed as first-line treatment in mild acne, whereas for moderate and severe acne, systemic therapy is required in addition to topical therapy. Currently, several topical agents are available that affect at least one of the main pathogenetic factors responsible for the development of acne. Although topical therapy has an important position in acne treatment, side effects associated with various topical antiacne agents and the undesirable physicochemical characteristics of certain important agents like tretinoin and benzoyl peroxide affect their utility and patient compliance. Novel drug delivery strategies can play a pivotal role in improving the topical delivery of antiacne agents by enhancing their dermal localization with a concomitant reduction in their side effects. The current review emphasizes the potential of various novel drug delivery strategies like liposomes, niosomes, aspasomes, microsponges, microemulsions, hydrogels and solid lipid nanoparticles in optimizing and enhancing the topical delivery of antiacne agents.

show abstract

Section: Overview Of Various Novel Drug Delivery Strategiesmentioning

confidence: 99%

Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents

Date

Naik²,

Nagarsenker³

2005

Skin Pharmacol Physiol

107

View full text Add to dashboard Cite

show abstract

“…Tretinoin 0.1% gel microsponge compared with tretinoin 0.025% gel, tazarotene 0.1% gel or adapalene 0.1% gel in a split face study showed similar facial tolerability for all retinoids [22]. A formulation of liposomally encapsulated tretinoin 0.01% was in a comparative study equipotent in clearing acne lesions as tretinoin 0.025 or 0.05% gel after once daily topical application for 10 weeks, but showed a much better cutaneous tolerability [23]. This was also reproducible on in vitro reconstructed epidermis [24].…”

Section: Tretinoinmentioning

confidence: 99%

Topical Treatment in Acne: Current Status and Future Aspects

Gollnick

Krautheim²

2003

Dermatology

110

View full text Add to dashboard Cite

During the last 20 years, the number of topical and systemic drugs for the treatment of acne vulgaris has been enriched. Topical drugs on the one hand have been newly discovered or further developments of already available agents such as in the group of retinoids or galenic formulation have improved efficacy or local tolerance. Topical retinoids are a mainstay in acne treatment since 1962. All-trans retinoic acid was the first and is still in use. Its irritative potential has led to the new galenics, i.e. incorporation in microsponges and in propolyomers, which increased the tolerability significantly. The isomer of tretinoin, isotretinoin, has the same clinical efficacy, but also a lower irritancy. A real breakthrough was adapalene, a retinoid-like agent, with a different retinoid receptor-binding profile, but in addition to the same clinical efficacy on inflammatory and non-inflammatory acne lesions compared to tretinoin, a better tolerability and, therefore, compliance. Unfortunately, over the past years topical retinoids have been less used in inflammatory acne than they should be, taking the the mechanisms of action into account. Topical antimicrobials, in particular topical antibiotics, should be used less often than in the past and only for short periods to avoid the development of resistances. It seems better to combine those agents with topical retinoids, with BPO or with azelaic acid to enhance the efficacy and slow down the development of resistance. BPO is still the gold standard for papular-pustular acne of mild-to-moderate type in concentrations of 2–5%. Azelaic acid is an alternative with efficacy on the comedo and is antibacterial without development of resistances. Finally, the physical removal by electrocautery or CO₂ laser of multiple densely packed closed comedones, macrocomedones and microcysts is necessary to enhance the efficacy of topical comedolytic agents and to speed up the therapeutic results. Photodynamic therapy has not yet been proven efficacious in controlled studies. Blue and red light can probably be used in association with local agents but enhancement of the irritative potential of topical and systemic agents has to be considered.

show abstract

“…The low DHT formation in DPC suggests that androgen receptor antagonists may be more effective than 5·-reductase inhibitors in androgenetic alopecia. To avoid systemic side effects, antiandrogen targeting to cutaneous appendices is highly needed [31,32].…”

Section: Discussionmentioning

confidence: 99%

Testosterone Metabolism in Human Skin Cells in vitro and Its Interaction with Estradiol and Dutasteride

Münster¹,

Hammer²,

Blume-Peytavi

et al. 2003

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Since the limited knowledge of cutaneous drug metabolism can impair the development of specifically acting topical dermatics and transdermal application systems, the cell-type-specific androgen metabolism in human skin and its inhibition by drugs were investigated. Cultured human foreskin and scalp skin keratinocytes and fibroblasts as well as occipital scalp dermal papilla cells (DPC) were incubated with testosterone 10^–6 and 10^–8M alone and in the presence of 17α-estradiol, 17β-estradiol or dutasteride for 24 h. Androgens extracted from culture supernatants were subjected to thin-layer chromatography and quantified by β-counting. In keratinocytes and DPC, dihydrotestosterone (DHT) was only formed to a low extent while androstenedione was the main metabolite. In fibroblasts, DHT formation was pronounced following 10^–8M testosterone. Dutasteride 10^–8M completely suppressed 5α-dihydro metabolite formation. 17α-Estradiol and 17β-estradiol at nontoxic concentrations decreased 17-ketometabolites. Human skin regulates testosterone action by cell-type-specific activation or deactivation. Effects of 17α-estradiol in androgenetic alopecia are not due to 5α-reductase inhibition. Dutasteride may be useful in acne and androgenetic alopecia.

show abstract

Liposomal tretinoin for uncomplicated acne vulgaris

Cited by 69 publications

References 20 publications

Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents

Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents

Topical Treatment in Acne: Current Status and Future Aspects

Testosterone Metabolism in Human Skin Cells in vitro and Its Interaction with Estradiol and Dutasteride

Contact Info

Product

Resources

About